What are the key takeaways from this Freakonomics Radio episode?

Key insights include: **Drug Approval Speed:** FDA reduces application review time from one year to weeks by convening offices simultaneously rather than sequentially, making decision letters public so companies understand exact approval criteria and rejection reasons, eliminating the black box regulatory process.; **Animal Testing Elimination:** Organ-on-chip technology and computational modeling prove more predictive than animal testing, which has 90% failure rate for human safety. FDA eliminates requirements starting with monoclonal antibodies, which currently use average 144 chimpanzees per drug tested.; **Priority Review Incentives:** Companies receive expedited FDA review worth $500 million if they commit to most-favored-nation pricing matching other developed countries, manufacture domestically for national security, or address large unmet public health needs, using market forces to lower drug costs.

What did Marty Makary discuss on Freakonomics Radio?

FDA Commissioner Marty Makary discusses his plans to accelerate drug approvals, eliminate animal testing requirements, modernize food guidelines, regulate AI in healthcare, and address autism treatments while navigating political controversies in the Trump administration. Key topics include: **Drug Approval Speed:** FDA reduces application review time from one year to weeks by convening offices simultaneously rather than sequentially, making decision letters public so companies understand exact approval criteria and rejection reasons, eliminating the black box regulatory process.; **Animal Testing Elimination:** Organ-on-chip technology and computational modeling prove more predictive than animal testing, which has 90% failure rate for human safety. FDA eliminates requirements starting with monoclonal antibodies, which currently use average 144 chimpanzees per drug tested..

How long is this episode of Freakonomics Radio?

This episode is 55 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Freakonomics Radio

659. Can Marty Makary Fix the F.D.A.?

January 16, 2026

55 min episode · 2 min read

Marty Makary

Episode

55 min

Read time

2 min

Topics

Health & Wellness, Fundraising & VC, Sales & Revenue

AI-Generated Summary

Published Jan 16, 2026

Key Takeaways

✓Drug Approval Speed: FDA reduces application review time from one year to weeks by convening offices simultaneously rather than sequentially, making decision letters public so companies understand exact approval criteria and rejection reasons, eliminating the black box regulatory process.
✓Animal Testing Elimination: Organ-on-chip technology and computational modeling prove more predictive than animal testing, which has 90% failure rate for human safety. FDA eliminates requirements starting with monoclonal antibodies, which currently use average 144 chimpanzees per drug tested.
✓Priority Review Incentives: Companies receive expedited FDA review worth $500 million if they commit to most-favored-nation pricing matching other developed countries, manufacture domestically for national security, or address large unmet public health needs, using market forces to lower drug costs.
✓Leucovorin for Autism: FDA approves generic drug leucovorin for cerebral folate deficiency in autism based on clinical trials showing 20% of children with severe autism have marked improvement, 30-40% show some benefit by bypassing blocked folate receptors in brain.

What It Covers

FDA Commissioner Marty Makary discusses his plans to accelerate drug approvals, eliminate animal testing requirements, modernize food guidelines, regulate AI in healthcare, and address autism treatments while navigating political controversies in the Trump administration.

Key Questions Answered

•Drug Approval Speed: FDA reduces application review time from one year to weeks by convening offices simultaneously rather than sequentially, making decision letters public so companies understand exact approval criteria and rejection reasons, eliminating the black box regulatory process.
•Animal Testing Elimination: Organ-on-chip technology and computational modeling prove more predictive than animal testing, which has 90% failure rate for human safety. FDA eliminates requirements starting with monoclonal antibodies, which currently use average 144 chimpanzees per drug tested.
•Priority Review Incentives: Companies receive expedited FDA review worth $500 million if they commit to most-favored-nation pricing matching other developed countries, manufacture domestically for national security, or address large unmet public health needs, using market forces to lower drug costs.
•Leucovorin for Autism: FDA approves generic drug leucovorin for cerebral folate deficiency in autism based on clinical trials showing 20% of children with severe autism have marked improvement, 30-40% show some benefit by bypassing blocked folate receptors in brain.

Notable Moment

Makary reveals aspirin would never have been approved under traditional animal testing protocols despite being a powerful medication for humans, demonstrating how current regulatory requirements may block beneficial treatments that fail animal models but work in people.

Know someone who'd find this useful?

Episode Transcript

When it comes to public health, the first year of the second Trump administration has been an unusually busy one and unusually controversial. Most of this has run through Robert F Kennedy Junior, the Secretary of Health and Human Services. In just the past few weeks, Kennedy overhauled the government's recommendations for childhood vaccines and revised the so called food pyramid promoting animal proteins especially, while downgrading ultra processed foods, refined carbohydrates, and added sugars. Kennedy's policies affect several agencies under his purview including the Food and Drug Administration. The FDA has had a busy year of its own approving new treatments for several rare diseases including cancers, as well as for rheumatoid arthritis and HIV. The agency also approved a non opioid pain medicine, the first of its kind in many years. The next few years may be even busier. The FDA today is not going to be an FDA in a receive only mode. We're not gonna be stingy librarians. We're gonna go into the pipeline, find out what sounds promising, and bring that to the forefront. That is Marty McCary, commissioner of the FDA. He has been on Freakonomics Radio a few times in the past, and he made a brief appearance in last week's episode about brain supplements. McCary was a longtime surgical oncologist and professor of surgery at Johns Hopkins University. He's also done a lot of health policy research. He's published hundreds of papers and three books that critiqued the American health care system. Running the FDA is McCary's first job in government, and he knows it's a big one. The FDA regulates 20% of The US economy, and there are so many aspects to the FDA. And there are so many things broken at the FDA. I spoke with McCary in October, but our release of this episode was delayed by the government shutdown. What's interesting is just how timely the conversation feels right now. It's always good to get an insider's view from an institution like the FDA. So today, as we continue our Freakonomics Radio guide to getting better, Marty Makary on food recommendations, drug approvals, public health, and what people in the White House like to call Trump Derangement Syndrome. If literally we had discovered and announced the cure for cancer, you would have some people say, well, the Trump administration interfered. They did this too quick. They did it too slow. What exactly does Marty Makary's FDA want to accomplish? That's coming up starting now. This is Freakonomics Radio, the podcast that explores the hidden side of everything with your host, Stephen Dubner. Hey, Stephen. Marty, how are you? Hey. Great. It's been a while. Can I still call you Marty even though you're Yes? What have been the biggest adjustment for you so far in moving from a life of a physician scientist and author, surgical oncologist now to a government regulator? Any details or stories would be appreciated. I was in the Operating Room the day before …

Get the full transcript (8,563 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Freakonomics Radio transcripts →